Amneal Pharmaceuticals, Inc. financials

  1. Home
  2. Financials
  3. AMRX
AMRX CIK 0001723128

Source: EDGAR filings · Built 2026-06-02T02:19:43Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 266.51M 239.92M 298.77M 15.21M 190.91M 319.79M
EBITDA 617.70M 485.53M 433.77M 145.27M 386.12M 326.54M
Working Capital 1.03B 458.04M 531.27M 659.02M 842.87M 874.64M
Net Debt 2.41B 2.38B 2.44B 2.72B 2.59B 2.57B
Gross Margin 36.88% 36.52% 34.28% 35.47% 36.73% 31.54%
Operating Margin 13.05% 8.92% 8.54% -4.29% 7.29% 4.57%
Net Margin 2.39% -4.18% -3.51% -12.23% 0.63% 3.40%
Return on Equity (ROE) -101.78% 106.97% -424.61% -90.67% 3.65% 22.35%
Return on Assets (ROA) 1.96% -3.34% -2.42% -7.12% 0.33% 1.69%
Current Ratio 2.17× 1.41× 1.63× 1.88× 2.24× 2.29×
Debt-to-Equity -37.98× -22.82× 127.90× 9.20× 7.88× 9.59×
Effective Tax Rate 8.10% -34.29% -20.99% -2.68% 35.69% 291.67%
Cash Conversion Ratio 4.72× -2.52× -4.11× -0.24× 18.37× 5.59×
Accruals Ratio -0.07× -0.12× -0.12× -0.09× -0.06× -0.08×
SBC % of Revenue 1.06% 0.99% 1.12% 1.44% 1.36% 1.04%
CapEx Coverage 4.63× 5.35× 7.38× 1.30× 4.75× 6.40×
Free Cash Flow Per Share $0.82 $0.78 $1.70 $0.10 $1.26 $2.15

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 57.27× — — — 68.43× 7.49×
P/FCF 15.36× 10.20× 3.58× 19.74× 3.81× 2.13×
FCF Yield 6.51% 9.80% 27.95% 5.07% 26.25% 46.99%
EV / EBITDA 10.31× 9.96× 9.92× 20.79× 8.59× 9.94×
P/S 1.31× 0.88× 0.78× 0.14× 0.35× 0.34×
P/B — — 94.21× 1.01× 2.02× 2.24×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 3.02B 2.79B 2.39B 2.21B 2.09B 1.99B
Cost of Goods and Services Sold 1.91B 1.77B 1.57B 1.43B 1.32B 1.33B
Gross Profit 1.11B 1.02B 820.57M 784.71M 768.97M 628.39M
Research and Development Expense 186.18M 190.71M 163.95M 195.69M 201.85M 179.93M
Selling, General and Administrative Expense 526.83M 476.44M 429.68M 399.70M 365.50M 326.73M
Operating Income (Loss) 394.10M 249.33M 204.37M -94.93M 152.72M 91.16M
Income Tax Expense (Benefit) 11.28M 18.86M 8.45M 6.66M 11.20M -104.36M
Net Income (Loss) Attributable to Parent 72.06M -116.89M -83.99M -270.58M 13.16M 67.79M
Earnings Per Share, Basic $0.23 $-0.38 $-0.48 $-0.86 $0.07 $0.62
Weighted Average Number of Shares Outstanding, Basic 313.37M 308.98M 176.14M 150.94M 148.92M 147.44M
Earnings Per Share, Diluted $0.22 $-0.38 $-0.48 $-0.86 $0.07 $0.61
Weighted Average Number of Shares Outstanding, Diluted 324.81M 308.98M 176.14M 150.94M 151.82M 148.91M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 282.03M 110.55M 91.54M 25.98M 247.79M 341.38M
Assets, Current 1.91B 1.59B 1.38B 1.41B 1.52B 1.55B
Assets 3.68B 3.50B 3.47B 3.80B 3.94B 4.01B
Long-term Debt 2.57B 2.39B 2.42B 2.62B 2.71B 2.78B
Liabilities, Current 881.63M 1.13B 846.60M 752.80M 677.24M 676.90M
Long-term Debt, Excluding Current Maturities 2.57B 2.16B 2.39B 2.59B 2.68B 2.74B
Stockholders' Equity Attributable to Parent -70.79M -109.27M 19.78M 298.42M 360.34M 303.27M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 339.99M 295.10M 345.58M 65.10M 241.82M 379.00M
Payments to Acquire Property, Plant, and Equipment 70.06M 51.92M 43.22M 46.41M 47.73M 56.45M
Net Cash Provided by (Used in) Investing Activities -112.26M -63.00M -69.19M -174.31M -194.18M -317.55M
Payments of Dividends — — — — — 0
Net Cash Provided by (Used in) Financing Activities -31.53M -211.79M -212.57M -106.62M -138.12M 131.81M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (AMRX CIK 0001723128), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

GEF

GREIF, INC.

PODC

PodcastOne, Inc.

AMC

AMC ENTERTAINMENT HOLDINGS, INC.